Clinically useful non-steroidal antiandrogen (IC50 = 36 nM) for the treatment of castration-resistant prostate cancer.1,2 It impairs binding of the androgen receptor to DNA, the recruitment of co-activators, and reduces the efficiency of nuclear transloc
* VAT and and shipping costs not included. Errors and price changes excepted